Status:

COMPLETED

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

Lead Sponsor:

Novartis

Conditions:

De Novo Renal Transplantation

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The primary aim of this study is to evaluate the safety and efficacy of EC-MPS plus valsartan as part of an intensified multifactorial intervention on the reduction of the 12-month rate of transplant ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • 1\. Male and female patients aged 18 to 70 years 2. Patients receiving a first kidney transplant from a cadaver donor, who are scheduled to receive CsA-ME and anti-CD25 antibody as primary immunosuppression; 3. Patients able to receive the first dose of EC-MPS within 48 hours of graft reperfusion Exclusion criteria
  • Multi-organ recipients (e.g. kidney and pancreas, double kidney) or previous transplant with any other organ.
  • Recipient of a kidney from a non-heart beating, from a cadaver donor aged more than 70 years, or with cold ischemia time of more than 36 hours
  • Recipient who is HLA-identical to the donor
  • Patients with a PRA level (past or current level) higher than 50%
  • Patients with a known hypersensitivity to EC-MPS or other components of the formulation (e.g. lactose).
  • Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline.
  • HIV-positive
  • Positive HBsAg test for both donor and recipients.
  • Unstable angina, acute myocardial infarction or stroke during the last 6 month or heart failure NYHA class III-IV or hemodinamically significant valvular heart disease
  • Liver injury as indicated by transaminase serum levels (ALT and/or AST) greater than 2 x ULN
  • Creatinine kinase (CK) levels greater than 5 x ULN. Additional protocol-defined inclusion/exclusion criteria may apply

Exclusion

    Key Trial Info

    Start Date :

    October 1 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2005

    Estimated Enrollment :

    119 Patients enrolled

    Trial Details

    Trial ID

    NCT00308425

    Start Date

    October 1 2002

    End Date

    June 1 2005

    Last Update

    January 31 2011

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.